The role of pharmacoepidemiological studies in the market withdrawal of carisoprodol (Somadril®) in Europe, 167-172

Authors

  • Jørgen G. Bramness NTNU
  • Ingebjørg Buajordet
  • Svetlana Skurtveit

DOI:

https://doi.org/10.5324/nje.v18i2.29

Abstract

Carisoprodol is a centrally acting muscle relaxant that has been marketed in Europe for more than 45 years. In November 2007 the European Medicines Association recommended suspension of all carisoprodol containing products in all EU countries. During recent years, several observational studies on carisoprodol have been published by our group, which works in the field of traffic medicine and pharmacoepidemiological research in general. In this paper, we review the role pharmacoepidemiological studies on carisoprodol played in providing evidence for the risk of psychomotor impairment and traffic accidents, intoxications and abuse. These issues have been important for decisions about the regulation of carisoprodol. Key words: pharmacoepidemiology, carisoprodol, drug abuse, impairment, intoxication

Downloads

Download data is not yet available.

Downloads

Published

2009-09-28

How to Cite

Bramness, J. G., Buajordet, I., & Skurtveit, S. (2009). The role of pharmacoepidemiological studies in the market withdrawal of carisoprodol (Somadril®) in Europe, 167-172. Norsk Epidemiologi, 18(2). https://doi.org/10.5324/nje.v18i2.29

Issue

Vol. 18 No. 2 (2008): Pharmacoepidemiology

Section

Articles

License

Norsk Epidemiologi licenses all content of the journal under a Creative Commons Attribution (CC-BY) licence. This means, among other things, that anyone is free to copy and distribute the content, as long as they give proper credit to the author(s) and the journal. For further information, see Creative Commons website for human readable or lawyer readable versions.

Authors who publish with this journal agree to the following terms:

1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).